EURORealTime APOE and Alzheimer’s Biomarker Panels
EUROIMMUNThe EURORealTime APOE enables precise determination of the APOE genotype to support risk assessment prior to anti-amyloid therapy for Alzheimer’s disease. The test includes automated data analysis for easy result readout. Only one reaction is required per sample. To support early diagnosis of the disease, EUROIMUN offers biomarker assays for robust measurement of beta amyloid, total tau and p-Tau(181) in CSF.